
å¥èšºã§LDLæ£åžžã ã£ã人ã»ã©ãäžåºŠApoBãæž¬ã£ãŠã»ãã
ãLDLã¯æ£åžžã§ããã
倿¥ã§ãèªåã¯ãã®èšèãäœåºŠã䜿ã£ãŠããã
è質ç°åžžçã®æ£è ããã蚺ããšãããŸã確èªããã®ã¯LDLã³ã¬ã¹ãããŒã«ã ã£ããããã¯ä»ã§ãééãã§ã¯ãªããLDLã¯åè硬åã®ãªã¹ã¯ãèããããã§ã倧äºãªæ°åã ã
ãã æè¿ã¯ããã®äžèšã ãã§å®å¿ãããã®ãå°ãæããªã£ãŠãããLDLãåºæºå€å ã§ããè¡ç®¡ãªã¹ã¯ãæ®ã人ãããããã ããã®ç²ç¹ãæŸãæãããã®äžã€ããApoBãšããè¡æ¶²æ€æ»ã ã
ApoBãã¢ããªãã¿ã³ãã¯BãšãåŒã°ããã
å¥èšºã§èª¿ã¹ãããšã¯å°ãªãããæ¥åžžèšºçã§æèããŠããå»åž«ã決ããŠå€ãã¯ãªããšæããèªåãããã§ãLDLãHDLãäžæ§èèªã確èªããã°ã ããã倿ã§ãããããæã£ãŠããã
ã§ãã2024幎ã«åŸªç°åšé åã®äž»èŠèªããApoBã«é¢ããéèŠãªè«æãçžæ¬¡ãã ãããã§èªåã®äžã®ãLDLã ã远ã£ãŠããã°ååããšããæèŠãæºããã ã
ãã®èšäºã§äŒãããããšã¯ãã²ãšã€ã ãã ãå¥èšºã§LDLãæ£åžžã ã£ã人ã»ã©ãäžåºŠApoBãæž¬ã£ãŠã»ããã
LDLã¯è·ç©ã®éãApoBã¯è»ã®å°æ°
é£ãã話ã®åã«ããŸãã€ã¡ãŒãžãã
è¡ç®¡ããã³ãã«ã ãšãããã³ã¬ã¹ãããŒã«ãè·ç©ããããéã¶å°ããªç²åãè»ã ãšæã£ãŠã»ãããè»ãã³ã¬ã¹ãããŒã«ãšããè·ç©ãéãã§ããã
LDLã¯ãè·ç©ã®ãéãã
ApoBã¯ãè»ã®ãå°æ°ãã
åãè·ç©ã®éã§ããéã¶è»ã倧åãã©ãã¯1å°ãªã®ããã€ã¯50å°ãªã®ãã§ããã³ãã«ã®æ··ã¿æ¹ã¯å€ããã倧ããªãã©ãã¯ã1å°éããããå°ããªè»ãäœåå°ãã²ããããŠããã»ãããå£ã«ã¶ã€ãã£ãŠå
¥ã蟌ã¿ãããããªæ°ãããªãã ããããã ãããããã®æèŠã§åã£ãŠãããåè硬åã§ã¯ããã®ãå°æ°ããå¹ããŠããã
LDLãåãã§ããApoBãé«ã人ã¯ãè·ç©ã®ç·éã¯åããªã®ã«è»ã®æ°ãå€ããç¶æ
ã«ãªãããã
Aãã¿ãŒã³ã è·ç©ã®éã¯åããã§ããè»ã®å°æ°ã¯å°ãªãã
Bãã¿ãŒã³ã è·ç©ã®éãåããã§ããè»ã®å°æ°ãå€ãã
å¥èšºã®LDLã ãã§ã¯ããã®å·®ãæŸãã«ãããã ãããLDLã¯æ£åžžããšèšããã人ã®äžã«ãApoBã§ç¢ºèªãããšãªã¹ã¯ãæ®ã£ãŠããäººãæ··ããããããæŸãããã

å°éçã«ã¯ããã®è»ãããªãã¿ã³ãã¯ç²åããšåŒã¶ãååã¯èŠããªããŠãããApoBãæã€ç²åãè¡ç®¡ã®å£ã«å ¥ã蟌ã¿ãããã§ççããã©ãŒã¯åœ¢æã«ã€ãªãã£ãŠããã
ã±ããžã§ããã¯ãã€ãšããã§ãApoBã¯73ãã110ã«ãªã£ã
èªåã«ããApoBã倧ããäžãã£ãçµéšããããã±ããžã§ããã¯ãã€ãšãããæ¬æ°ã§ãã£ããšãã ãã±ããå§ããåãLDLã¯112mg/dLãApoBã¯73mg/dLã ã£ãã1ãæã»ã©ç¶ããããšã¯ãLDLã182ãApoBã110ã«ãªã£ãŠããã

ApoBã®æ£åžžå€ã¯73ã109mg/dLãããâ¶âŸãå§ããåã¯äžéããããã1ãæåŸã¯äžéãè¶
ããŠããããã£ãã®æ¯å©ã§èšãã°ãè·ç©ã®éã1.6åã«ãªããè»ã®å°æ°ã1.5åã«ãªã£ãŠãããLDLãäžãã£ãŠããç²åã倧ãããªã£ãã ãã§å°æ°ã¯å€ãããªã人ããããèªåã®å Žåã¯ãå°æ°ãã®ãã®ãå¢ããŠããã
äœéã¯èœã¡ããäžæ§èèªã¯äœããHDLãé«ããäœèèªçãäœãã£ããäœèª¿ãããã£ããããã§ããåè硬åã«é¢ããç²åã®æ°ã¯å¢ããŠãããäœéãèœã¡ãããšããããã®æ°åã®ã»ãã倧äºã ã£ãã
ãã¡ããã110ãšããæ°åã ãã§æ²»çãå¿
èŠãšæ±ºãŸãããã§ã¯ãªãããã§ã«å¿è¡ç®¡çŸæ£ãããããç³å°¿ç
ãè
èã®ç
æ°ãå«ç
ãªã©ã®ãªã¹ã¯ããããã§ãApoBã®è©äŸ¡ãç®æšã¯å€ãã¹â°âŸãããã§ãèªåã®å Žåã¯ããã®æ°åããã£ããããã±ãã§ç©ããããšããã®ãŸãŸæåãšã¯åŒã¹ãªããªã£ãã
ã¡ãªã¿ã«ãã±ããžã§ããã¯ãã€ãšããã®äœéšè«ã¯ãã¡ãã«æžããã
ApoBã®æž¬å®ãçžè«ããã人
ã§ã¯ãã©ããªäººã枬ãæå³ãããã®ããèªåã¯ãå¥èšºã§LDLãæ£åžžã ã£ã人ã»ã©äžåºŠæž¬ãæå³ããããšæã£ãŠãããç¹ã«ã次ã®é ç®ã«åœãŠã¯ãŸã人ã ã
äžæ§èèªãé«ã
HbA1cãé«ã
BMIã25以äž
è ¹å²ãå¢ããŠãã
ã¹ã¿ãã³ã飲ãã§ããŠLDLã ãããã§ãã¯ããŠãã
éçµåŸã§LDLãã ãã ãäžãã£ãŠãã
å®¶æã«è¥ãããŠå¿çæ¢å¡ãè³åäžãèµ·ããã人ããã
äœç³è³ªãã±ãã§LDLã倧ããäžãã£ãããšããã
è€æ°åœãŠã¯ãŸããªããæ¬¡ã®æ¡è¡ã§ApoBã®æž¬å®ãçžè«ãã䟡å€ã¯ããã1ã€ã ãã§ããå®¶ææŽããã人ããLDLã¯æ£åžžã ãã©æ¬åœã«å®å¿ããŠããã®ãããæ°ã«ãªã人ã¯ãäžåºŠæž¬ã£ãŠãããšã远å ã®å€æææã«ãªãã
ApoBã ãã§å¿çæ¢å¡ãäºèšã§ããããã§ã¯ãªãã
ããã§ããæ¬¡ã®æ¡è¡ã«1é ç®è¶³ãã ãã§ãLDLã ãã§ã¯æŸãã«ãããç²åã®æ°ãã確èªã§ãããè¡ç®¡ãªã¹ã¯ãäžæ®µçްããåããã«ã¯ãããæãããã«ãªãã
åãLDLã§ããApoBã§ãªã¹ã¯ã¯ãºã¬ã
çå±ã ãã§ã¯ãªããåé ã§è§Šãã2024幎ã®è«æãããã ãåãLDLã§ãApoBã§ãªã¹ã¯ãéãããšãã3ã€ã®ç ç©¶ã瀺ããŠããã
UKBiobankã®çŽ29äžäººããäžå€®å€çŽ11幎远跡ããç 究¹âŸ
LDLãåããããã§ããApoBãé«ã人ãšäœã人ã§ãå¿çæ¢å¡ãè³åäžãªã©ã®ãªã¹ã¯ã«å·®ããã£ã
ããšãã°LDLã130mg/dLååŸã®äººãã¡ã§ã¯ã10幎ãªã¹ã¯ã¯ApoBãé«ã矀ã§7.3%ãäœã矀ã§4.0%ã ã£ã
LDLããèŠãŠããªããšããã®å·®ãèŠèœãšã

芳å¯ç ç©¶ãªã®ã§ãApoBãäžããã°ãã®ã¶ãçºçãæžãããšãã®ç ç©¶ã ãã§ã¯èšãåããªããåå è ã®èæ¯ãæ¥æ¬äººãã®ãã®ã§ã¯ãªããããã§ããåãLDLã§ãApoBã§ãªã¹ã¯ããºã¬ãããšã¯ç¡èŠãã«ããã
ã³ãã³ããŒã²ã³ã®äžè¬äœæ°ã远跡ããç 究²âŸ
LDLããäºæž¬ãããããApoBãå€ãç¶æ ã¯ãå¿çæ¢å¡ãè³åäžãªã©ã®ãªã¹ã¯äžæãšé¢é£ããŠãã
ApoBãäºæž¬ããããªãå€ã矀ã§ã¯ããªã¹ã¯ã瀺ããã¶ãŒãæ¯ã女æ§ã§æå€§1.75ãç·æ§ã§æå€§1.52ã ã£ã
ç·å¥³ã©ã¡ãã§ããäºæž¬ãšã®ãºã¬ã倧ããã»ã©ãªã¹ã¯ã¯äžãã£ãŠãã
女æ§ã®ã»ããå±ãªããšããããã§ã¯ãªãããã ãéçµåŸã¯èè³ªãæªåãããããå¥èšºã§LDLã倧ããå€ããŠããªããŠããApoBãšäžæ§èèªãããã«HbA1cãè
¹å²ãŸã§äžŠã¹ããšå€æãå€ãã人ãããã
ç±³åœNHANESã§ãLDLãåã人ã®äžã®ApoBã®ã°ãã€ãã調ã¹ãç 究³âŸ
LDLã100mg/dLã®äººã§ããApoBã¯66ã99mg/dLãŸã§å¹ ããã£ã
LDL100ãšããåãæ°åã®äžã«ãApoBãããªãäœã人ããé«ãã®äººãæ··ãã£ãŠãã
代è¬çã«å¥åº·ãšããã人ã®äžã«ããApoBãLDLããäºæ³ãããããé«ã人ããã
ãèªåã¯ä»£è¬ç°åžžããªããããLDLãšApoBã¯ã ãããäžèŽããŠããã¯ãããšæããããããªãããããšãéããªããæšæž¬ã§ã¯ããããªããããæž¬ããããªãã
2025幎ã®ç ç©¶ã¯ãè»ã®çš®é¡ãŸã§ç¢ºèªãã
2025幎ã«ã¯ãUKBiobankã®37äžäººä»¥äžã䜿ã£ãŠãLDLãšApoBã®ãºã¬ãããäžæ®µçްãã調ã¹ãç ç©¶ãå ±åãããâŽâŸã察象ã¯ãç ç©¶éå§æç¹ã§å¿è¡ç®¡çŸæ£ããªããè質ãäžããè¬ã䜿ã£ãŠããªã人ãã¡ã ã
ç ç©¶ããŒã ã¯ãLDLã®é«ããšApoBã®é«ãããºã¬ãŠãã人ãåãããåçŽã«èšãã°ããLDLã¯ãããŸã§é«ãèŠããªãã®ã«ãApoBã¯çžå¯Ÿçã«é«ã人ããæŸã£ãç ç©¶ã ã
ãã®ç ç©¶ã®èã¯ãNMRãšããæ¹æ³ã§ãè¡æ¶²äžãæµãããªãã¿ã³ãã¯ç²åã®çš®é¡ãŸã§ç¢ºèªããŠãããšããã ããã£ãã®æ¯å©ã§èšãã°ãè»ã®å°æ°ã ãã§ãªããè»ã®çš®é¡ãŸã§åãã«ãã£ãã
çµæã¯ããã¯ãåãã ã£ãã
LDLã«æ¯ã¹ãŠApoBãé«ã人ã§ã¯ãå¿çæ¢å¡ãè³åäžãªã©ãå«ãäž»èŠãªå¿è¡ç®¡ã€ãã³ããå€ãã£ã
éã«ãLDLã«æ¯ã¹ãŠApoBãäœã人ã§ã¯ããªã¹ã¯ãäœãã£ã
ApoBãé«ã人ã§å¢ããŠããã®ã¯ãLDLã®è»ã ãã§ã¯ãªãã£ããVLDLãšãããäžæ§èèªãå€ãéã¶è»ãå¢ããŠãã
èšãæãããšããåãè·ç©ã®éã§ãè»ã®å°æ°ãå€ã人ãã®äžã«ã¯ãäžæ§èèªãç©ãã è»ã§å°æ°ãå¢ããŠãã人ããããããã芳å¯ç ç©¶ãªã®ã§ãApoBãäžãããã€ãã³ããæžããšãã®1æ¬ã§æ±ºããããããã§ã¯ãªãã察象ãUKBiobankãªã®ã§ãæ¥æ¬äººã«ãã®ãŸãŸæ°åãåœãŠã¯ããã®ã¯æ
éã«ãããã
ãã ãåãLDLã§ããè»ã®å°æ°ãšçš®é¡ãéã人ããããããšã¯ãã¯ã£ããããŠããã
è¬ã§LDLãäžããããšãApoBã¯ã©ããªãã
å€§èŠæš¡èšåºè©ŠéšFOURIERãšIMPROVE-ITãåãããŠçŽ4äžäººã®ããŒã¿ã䜿ã£ãè§£æãããâµâŸãåå è ã¯å šå¡ãã¹ã¿ãã³ã飲ãã§ããã
å¿çæ¢å¡ã®ãªã¹ã¯ãšé¢é£ããŠããã®ã¯ãApoBãå«ãç²åã®æ°ã ã£ã
ãã ãããã®é¢é£ã¯ããããææã«å±ãçšåºŠã§ã匷ããšã¯èšããªã
ããã§ããéãã§ããäžèº«ã®éãã€ãŸãã³ã¬ã¹ãããŒã«ãäžæ§èèªã§ã¯èª¬æãã€ããªãã£ã
è¬ã§LDLãäžããããšã«ã¯ããã¡ããæå³ããããã¹ã¿ãã³ã飲ãã§ãã人ã«ãè¬ã¯æå³ããªãããšèšãããããã§ã¯ãªãããããéã§ãLDLãäžãã£ãã®ã¯å€§ããªåé²ã ããã®ããã§ã確èªãããããšãäžã€æ®ãã
LDLã¯äžãã£ããã§ããApoBã¯ãŸã é«ãã
ãã®å Žåããªã¹ã¯ãæ®ã£ãŠããå¯èœæ§ãããã®ã§ãè¿œå æ²»çã®å¿
èŠæ§ã䞻治å»ãšçžè«ãããã
äœç³è³ªãã±ãã§LDLã倧ããäžãã£ã人ãåãã ãäžæ§èèªãäœãHDLãé«ããŠããèªåã®ApoBã¯73ãã110ã«äžãã£ãŠãããäœåãäœèª¿ããããŠããç²åã®æ°ã¯ApoBã§ç¢ºããããããããå
ã«äœã確ããããã¯ãå¥ã®èšäºã«ãŸãšããã
ç³è³ªå¶éã§LDLãäžãã£ãããäœã確ããããïŒç¡æïŒ
æ¬¡ã®æ¡è¡ã§ã©ãé Œãã°ããã
ããã ãã§ãããæ¥æ¬ã§ã¯ãã¢ããªãèçœã¯ä¿éºèšºçã§ç®å®ãããŠããæ€æ»é
ç®ã ã蚺çå ±é
¬äžã¯ãã¢ããªãèçœ1é
ç®ã§31ç¹ãšãããŠããâ¹âŸãæ€æ»ãã®ãã®ã®è²»çšã¯ã3å²è² æ
ãªã100åã»ã©ã ã
ãã ããå®éã®èªå·±è² æ
ã¯å Žé¢ã§å€ããã
èšºå¯æã倿æãçæŽ»ç¿æ £ç 管çæã®æç¡ã§å€ãã
ä¿éºèšºçããèªè²»å¥èšºãã§ãå€ãã
å»åž«åŽã¯ãç åã蚺çäžã®å¿ èŠæ§ãèããŠãªãŒããŒãã
人éããã¯ãèªè²»å¥èšºã§ã¯ãæœèšã«ãã£ãŠè¿œå è²»çšãéã
äŒç€Ÿå¥èšºã§ã¯ãé ç®ã«å ¥ããããªãããšããã
ã誰ã§ãã©ã®å Žé¢ã§ã100åã§æž¬ããããšã¯éããªããããã§ããApoBã¯ç¹æ®ãªæå ç«¯æ€æ»ã§ã¯ãªãæããããæ€æ»ã§ãçŸå®çã«çžè«ããããè¡æ¶²æ€æ»ã ãšæã£ãŠããã
ApoBãæž¬ãæµãã¯ãæµ·å€ã®ã¬ã€ãã©ã€ã³ã«ãããã2026幎ã®ACC/AHAç³»è質管çã¬ã€ãã©ã€ã³ã§ããåãæ¹éã瀺ãããâžâŸãLDLã ãã§ãªããApoBãéºäŒã®åœ±é¿ã匷ãLp(a)ãŸã§æž¬ããå¿èã®è¡ç®¡ã®ç³ç°åãCTã§èª¿ã¹ãå åèã«ã«ã·ãŠã ã¹ã³ã¢ã䜿ã£ãŠè¡ç®¡ãªã¹ã¯ã现ããåãããLDLã ãã§ã¯æŸããããªããªã¹ã¯ã確ãããææã«ãªãã®ã¯ãããšãã°æ¬¡ã®ãããªäººã
ç³å°¿ç ããã人
äžæ§èèªãé«ã人
ãã§ã«å¿è¡ç®¡çŸæ£ããã人
çµæã®èªã¿æ¹
ApoBã®åºæºå€ã¯ãæ€æ»äŒç€Ÿã§ã¯ç·æ§73ã109mg/dLã女æ§66ã101mg/dLãããã䜿ãããããšãããããã ããã®åºæºå€ã¯ãåãæ€æ»ãåãã人ãã¡ã®ååžããæ±ºããããç¯å²ãã«è¿ããè¡ç®¡ãªã¹ã¯ãã©ããŸã§äžãããããšã¯å¥ã®è©±ã ã
欧å·ESC/EASã¬ã€ãã©ã€ã³ã§ã¯ãApoBã¯LDLãªã©ãè£ãäºæ¬¡ç®æšãšããŠã以äžã®ãããªç®å®ã䜿ãããâ·âŸã
äžç床ãªã¹ã¯ïŒ100mg/dLæªæº
é«ãªã¹ã¯ïŒ80mg/dLæªæº
è¶ é«ãªã¹ã¯ïŒ65mg/dLæªæº
èªåã®ã±ãäžã®110ã¯ããã¡ã°ãç·©ãäžç床ãªã¹ã¯ã®ç®å®ãè¶
ããŠããã
äžæ¹ã§ãApoBã90mg/dLã ã£ããšãããæ€æ»äŒç€Ÿã®åºæºå€ã§ã¯ãæ£åžžãã®ç¯å²ã ãããã§ããæ¬¡ã®ãããªèæ¯ãããã°ã90ã§ã¯ç©è¶³ããªãããšãããã
ç³å°¿ç ããã
å®¶ææ§é«ã³ã¬ã¹ãããŒã«è¡çïŒFHïŒãçããã
å¿çæ¢å¡ãèµ·ãããããšããã
é žåèãšã³ãŒã§ãã©ãŒã¯ãææãããããšããã
倧äºãªã®ã¯ãæ°åãåç¬ã§èªãŸãªãããšã ã幎霢ãè¡å§ãHbA1cãäžæ§èèªãHDLã«å«ç
æŽãå®¶ææŽãæ¢åŸæŽãåãããŠçžè«ããã
ApoBã¯ãæ£åžžãç°åžžãããäžçºã§æ±ºããæ€æ»ã§ã¯ãªãã
è¡ç®¡ãªã¹ã¯ãããäžæ®µçްããåããããã®æ€æ»ã ã
ApoBãé«ãã£ãããäœãçžè«ããã
ãŸãã¯ããªãApoBãé«ãã®ããèããã
äžæ§èèªãé«ãã®ã
è¡ç³ãé«ãã®ã
äœéãè ¹å²ãå¢ããŠããã®ã
飜åèèªé žãå€ãé£äºã«ãªã£ãŠããªãã
å®¶ææŽãããã®ã
ãã§ã«åè硬åã®æèŠãããã®ã
é£äºã§ã¯ã飜åèèªé žãæžããããšãäžè¬çãªå¯Ÿçãæãç©ããã¿ãŒãè身ã®å€ãèãèåé¡ãå€ã人ã¯ãããããå€ããã ãã§è質ã®åå¿ãå€ããããšããããé£ç©ç¹ç¶ã倧äºã ã
éåã§ã¯ãæé žçŽ éåã倧äºã ãã©çãã¬ããããããçãã¬ã§ã€ã³ã¹ãªã³æåæ§ãäžãããšãè質代è¬ã«ã圱é¿ãããç¹ã«è ¹å²ãHbA1cãäžæ§èèªãæªåããŠãã人ã¯ãçãã¬ãå ããæçŸ©ã倧ããã
è¬ã¯ã䞻治å»ãšçžè«ãããã¹ã¿ãã³ããšãŒããããPCSK9é»å®³è¬ãªã©ãéžæè¢ã¯ããã€ããããApoBã¯æ²»çæ¹éãèããææã«ã¯ãªãããæ²»çãã®ãã®ã¯èæ¯ãªã¹ã¯ãšåãããŠæ±ºããã
ãããã«
ã±ãããããŠé£äºãæ»ããçãã¬ãç¶ãããé£ç©ç¹ç¶ãå¢ãããããã®åŸã®æž¬å®ã§ã¯ãèªåã®ApoBã¯60mg/dLååŸã ã£ãã
ApoBã¯ãLDLã ãã§ã¯åãããªãæ
å ±ãè£ãæ€æ»ã ãæ¬¡ã®æ¡è¡ã§ããã¢ããªãã¿ã³ãã¯Bãäžç·ã«æž¬ããŸããããšèããŠã¿ãŠã»ãããçµæãåºãããããã§ç®¡çãå€ãããã䞻治å»ãšè©±ãã
ãŸãšã
LDLã¯è·ç©ã®éãApoBã¯è»ã®å°æ°
åãè·ç©ã®éïŒLDLïŒã§ãè»ïŒApoBïŒãå€ãã»ããåè硬åã¯èµ·ããããã
UKBiobankçŽ29äžäººã®ç ç©¶ã§ã¯ãLDL130mg/dLååŸã§ã10幎ãªã¹ã¯ã«å·®ããã£ãïŒApoBé«å€çŸ€7.3%察äœå€çŸ€4.0%ïŒ
LDLãæ£åžžã§ãApoBãæ£åžžãšã¯éããªã
äžæ§èèªãHbA1cãè ¹å²ãå®¶ææŽãæ°ã«ãªã人ã¯ApoBã®æž¬å®ãçžè«ãã䟡å€ããããéçµåŸã«èè³ªãæªåãã人ãã¹ã¿ãã³ã飲ãã§ãã人ãåã
ãããŸã§èªãã§ãã ãã£ãŠãããããšãããããŸããã
圹ã«ç«ã£ãããã¹ããããããããšããããå±ã¿ã«ãªããŸãã
èªåã®äœã§ã詊ããå¥åº·ã®è©±ããããããªããŒãã§ãæ°æ¥ã«1æ¬ãããæžããŠããŸãããã²ãã©ããŒããŠããããšå¬ããã§ãã
ãã£ãšæ·±ãç¥ãããæ¹ãžïŒé¢é£èšäºïŒ
ApoBãæž¬ãåã§ããæå ã®å¥èšºç¥šããã§ããããšããããŸããæ¬¡ã«è¶³ãæ€æ»ã®é çªãã幎霢ãšå®¶ææŽã§å€ãããŸãã
ãªãŒã«Aã®æ»è§ãå¥èšºã§ã¯èŠããªãè¡ç®¡ãªã¹ã¯ïŒã¡ã³ããŒéå®ïŒ
人éããã¯ããªãŒã«Aã ã£ã50ä»£ã®æ£è
ããã«ãé žåèãšã³ãŒã§èŠã€ãã£ããã®ãããããsdLDL-CãApoBãLp(a)ãã©ãè¶³ããããŸã§æžããŠããŸããApoBã®æ°åããå®éã®ã±ãŒã¹ã§èªã¿ãã人åãã§ãã
å¥èšºãªãŒã«Aã§ãçµããããªãçç±ïŒã¡ã³ããŒéå®ïŒ
LDLã ãã§ãªããäžæ§èèªãšHDLã確èªãããã§ããHbA1cãALTãeGFRãŸã§å«ããŠãæ·±èªã¿ã®ä»æ¹ããŸãšããŠããŸããApoBãæž¬ãåã«ãæå
ã®å¥èšºç¥šããã§ããããšãå¢ããŸãã
å¥èšºã®ãªãã·ã§ã³æ€æ»ãå
šéšçãã«ããªããŠãããå
ç§å»ãèããé çªïŒã¡ã³ããŒéå®ïŒ
è
¹éšãšã³ãŒãé žåèãšã³ãŒããã§ãªãã³ãªã©ãApoBãšäžç·ã«èãããè¿œå æ€æ»ãåªå
é äœã§æŽçããŠããŸãã
ã¡ã³ããŒã·ãããDr.ãããã©ããã®ãç¥ãã
ã¡ã³ããŒã·ãããDr.ãããã©ãããéå¶ããŠããŸããXã»ç¡ænoteã§ã¯åºããªããããäžæ®µèžã¿èŸŒãã è©±ãæžããŠããŸãã
çµå¶è ã®äž»æ²»å»ãšããŠã倿¥ã§å®éã«è©±ããŠããå 容
è«æãèªã¿ãªããèªåã®äœã§è©Šãããå¹ããã»å¹ããªãã£ãèšé²
æ€æ»æ°å€ã®èªã¿æ¹ããµããªã»è¬ã®éžã³æ¹
ã¡ã³ããŒéå®ã®æ²ç€ºæ¿Q&A
æé¡1000åã§å šèšäºèªã¿æŸé¡ã§ããåããªãã£ããããè§£çŽã§ããŸããæ°ã«ãªã£ãæ¹ã¯ãèŠããŠã¿ãŠãã ããã
â»æ¬èšäºã¯äžè¬çãªå¥åº·ã»å»åŠæ å ±ã®æäŸãç®çãšãããã®ã§ãããç¹å®ã®å人ã«å¯Ÿãã蚺æã»æ²»çã»å»åŠçå©èšãè¡ããã®ã§ã¯ãããŸãããå¥åº·äžã®æžå¿µãããå Žåã¯ãå¿ ãå»çæ©é¢ãå蚺ããŠãã ãããèšäºã®æ å ±ã«åºã¥ãè¡åã®çµæã«ã€ããŠã¯ãçè ã¯è²¬ä»»ãè² ããããŸãã
åèæç®
1. Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal. 2024;45(27):2410-2418. doi:10.1093/eurheartj/ehae258
2. Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. Journal of the American College of Cardiology. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423
3. Sayed A, Peterson E, Navar AM. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiology. 2024;9(8):741-747. doi:10.1001/jamacardio.2024.1310
4. Du Y, Ding W, Ye Z, Song Y, Gao L, Gao Y, Yang W, Dou K, Guo Y. Impact of LDL-C and apolipoprotein B level discordance and associated lipoprotein particle alterations on cardiovascular outcomes in a large primary prevention population. European Journal of Preventive Cardiology. 2025;zwaf750. doi:10.1093/eurjpc/zwaf750
5. Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology. 2022;7(3):250-256. doi:10.1001/jamacardio.2021.5083
6. LSIã¡ãã£ãšã³ã¹. æ€æ»æ¡å
ãã¢ãèçœBïŒã¢ããªãèçœïŒã. åºæºå€ïŒç·æ§73ã109mg/dLã女æ§66ã101mg/dL.
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
8. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online March 13, 2026. doi:10.1161/CIR.0000000000001423
9. åçåŽåç. 蚺çå ±é
¬ã®ç®å®æ¹æ³ïŒå»ç§èšºçå ±é
¬ç¹æ°è¡šïŒD007 è¡æ¶²ååŠæ€æ». ã¢ããªãèçœïŒ1é
ç®31ç¹ïŒ2é
ç®62ç¹ïŒ3é
ç®ä»¥äž94ç¹ïŒä»€å6幎æ¹å®ïŒ.
10ïŒSoffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663. doi:10.1016/j.jacl.2024.08.013.